Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Sponsor: Nabiqasim Industries (Pvt) Ltd
Summary
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Official title: Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
800
Start Date
2025-10-30
Completion Date
2026-06-30
Last Updated
2026-04-17
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin+Linagliptin+Metformin
Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients
Locations (2)
Faisalabad clinics
Faisalabad, Punjab Province, Pakistan
Aap ka Clinic
Lahore, Punjab Province, Pakistan